Alrabiah Mona A, Hassan Amina A, Mubaraki Murad A, Albarrag Ahmed M, Dkhil Mohamed A, Somily Ali M, Delic Denis, Hafiz Taghreed A
Microbiology and Immunology Department, King Khaled University Hospital, Riyadh, 12372, Saudi Arabia.
National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt.
Infect Drug Resist. 2025 Mar 24;18:1581-1593. doi: 10.2147/IDR.S502165. eCollection 2025.
The rise of antibiotic resistance is a significant threat to global health, necessitating the exploration of novel antimicrobial agents. Glycerol monolaurate (GML) is known for its antimicrobial properties, primarily against Gram-positive bacteria, with limited evidence of efficacy against Gram-negative pathogens.
This study evaluated the antibacterial activity of GML alone and in combination with human serum albumin (HSA) against clinical isolates of carbapenem-resistant and vancomycin-resistant bacteria using MIC and time-kill assays.
Contrary to previous reports, we demonstrate that GML exhibits significant antibacterial activity against Gram-negative bacteria, including strains resistant to conventional antibiotics. It inhibited carbapenem-resistant isolates with MIC values ranging from 25 to 100 μg/mL for , and and showed bacteriostatic and bactericidal activity. The combination of HSA and GML enhanced this effect, showing potent bactericidal properties across all tested concentrations.
Current findings suggest that HSA-bound GML could be developed as a novel broad-spectrum antimicrobial agent targeting multidrug-resistant pathogens. Future research should focus on formulation optimization, in vivo efficacy studies, and preclinical evaluations to determine its therapeutic potential in clinical settings.
抗生素耐药性的上升对全球健康构成重大威胁,因此有必要探索新型抗菌剂。月桂酸甘油单酯(GML)以其抗菌特性而闻名,主要针对革兰氏阳性菌,对革兰氏阴性病原体的疗效证据有限。
本研究使用最低抑菌浓度(MIC)和时间杀菌试验,评估了GML单独以及与人类血清白蛋白(HSA)联合对耐碳青霉烯类和耐万古霉素细菌临床分离株的抗菌活性。
与先前的报道相反,我们证明GML对革兰氏阴性菌具有显著的抗菌活性,包括对传统抗生素耐药的菌株。它抑制耐碳青霉烯类分离株的MIC值范围为25至100μg/mL,对[具体菌株1]、[具体菌株2]显示出抑菌和杀菌活性。HSA与GML的组合增强了这种效果,在所有测试浓度下均显示出强大的杀菌特性。
目前的研究结果表明,与HSA结合的GML可开发成为一种针对多重耐药病原体的新型广谱抗菌剂。未来的研究应集中在制剂优化、体内疗效研究和临床前评估,以确定其在临床环境中的治疗潜力。